Form 4: Kiniksa Pharmaceuticals Director Richard S. Levy Reports Acquisition and Disposal of Shares

Director Richard S. Levy reports transactions involving Kiniksa Pharmaceuticals Class A Common Shares and Restricted Share Units on May 3, 2024.

Summary

• On May 3, 2024, Richard S. Levy, a director of Kiniksa Pharmaceuticals, engaged in transactions involving the company's Class A Common Shares and Restricted Share Units (RSUs).
• Levy acquired 747 Class A Common Shares through the vesting of Restricted Share Units.
• Concurrently, Levy disposed of 747 Class A Common Shares, also related to the vesting of RSUs.
• Following these transactions, Levy directly owns 8,524 Class A Common Shares and no Restricted Share Units.
• The RSUs vested immediately upon grant on May 3, 2024, with each RSU representing a contingent right to receive one Class A Common Share.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing transactions by a company insider. It doesn't inherently convey positive or negative sentiment.

Positives

• The vesting of RSUs indicates that the director is meeting certain performance or time-based milestones set by the company.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• Shareholders can monitor insider transactions to gain insights into management's perspective on the company's value and prospects.

Key Dates